Lipid-Based Drug Delivery Systems Community

Hi All,

 - Please Distribute Widely !! 

https://science360.aaps.org/science360/2025/webinars2025/4151016/

Twan Lammers obtained a DSc in Radiation Oncology from Heidelberg University in 2008 and a PhD in Pharmaceutical Technology from Utrecht University in 2009. The same year, he started the Nanomedicine and Theranostics group at RWTH Aachen University. In 2014, he was promoted to full professor of medicine at RWTH Aachen University Clinic. His group aims to individualize and improve disease treatment by combining drug targeting with imaging. He is included in the Clarivate Analytics list of Highly Cited Researchers. He serves as the past president of the Controlled Release Society and a council member of the European Society for Molecular Imaging.

Strategies to Promote Cancer Nanomedicine Performance and Clinical Translation

Nanomedicines are extensively explored for cancer therapy. By delivering drug molecules more effectively and more selectively to pathological sites, and by attenuating their accumulation in healthy organs and tissues, nanomedicines assist in improving the balance between (chemo)therapy efficacy and toxicity. The tumor accumulation of nanomedicines is traditionally ascribed to the EPR effect, which is highly variable, both in animal models and in patients. To address issues associated with tumor targeting heterogeneity, and to advance cancer nanomedicine clinical translation, we are working on systems and strategies to monitor and modulate tumor-targeted drug delivery. In the present lecture, several of these strategies will be highlighted, including image-guided interventions to prime tumor blood vessels and the microenvironment, as well as the use of imaging and tumor tissue biomarkers for patient stratification. In addition, a presentation of ongoing work focusing on better understanding the ability of nanomedicines to target metastases. Altogether, our efforts aim to establish rational and realistic ways forward towards promoting the performance and translation of cancer nanomedicines. This comprehensive approach seeks to enhance the efficacy and clinical applicability of nanomedicine-based cancer treatments.

Best regards,

Rusty